Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 019071

« Back to Dashboard

NDA 019071 describes UROCIT-K, which is a drug marketed by Mission Pharma and is included in one NDA. It is available from five suppliers. Additional details are available on the UROCIT-K profile page.

The generic ingredient in UROCIT-K is potassium citrate. There are two hundred and thirty-four drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the potassium citrate profile page.
Summary for 019071
Applicant:Mission Pharma
Ingredient:potassium citrate
Therapeutic Class:Therapeutic Nutrients/Minerals/Electrolytes
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 019071
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
UROCIT-K potassium citrate TABLET, EXTENDED RELEASE;ORAL 019071 NDA Mission Pharmacal Company 0178-0600 0178-0600-01 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (0178-0600-01)
UROCIT-K potassium citrate TABLET, EXTENDED RELEASE;ORAL 019071 NDA Mission Pharmacal Company 0178-0610 0178-0610-01 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (0178-0610-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength5MEQ
Approval Date:Aug 30, 1985TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength10MEQ
Approval Date:Aug 31, 1992TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength15MEQ
Approval Date:Dec 30, 2009TE:ABRLD:Yes

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.